Regeneron Pharmaceuticals, Inc. (REGN)
746.54
+6.97
(+0.94%)
USD |
NASDAQ |
Oct 09, 16:00
741.17
-5.37
(-0.72%)
After-Hours: 20:00
Regeneron Pharmaceuticals Free Cash Flow (Quarterly) : 521.80M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 521.80M |
| March 31, 2026 | 799.40M |
| December 31, 2025 | 880.00M |
| September 30, 2025 | 1.374B |
| June 30, 2025 | 737.60M |
| March 31, 2025 | 773.60M |
| December 31, 2024 | 995.80M |
| September 30, 2024 | 1.049B |
| June 30, 2024 | 143.10M |
| March 31, 2024 | 1.351B |
| December 31, 2023 | 776.20M |
| September 30, 2023 | 914.40M |
| June 30, 2023 | 888.50M |
| March 31, 2023 | 1.088B |
| December 31, 2022 | 1.468B |
| September 30, 2022 | -440.40M |
| June 30, 2022 | 410.80M |
| March 31, 2022 | 1.960B |
| December 31, 2021 | 2.218B |
| September 30, 2021 | 3.280B |
| June 30, 2021 | 478.20M |
| March 31, 2021 | 553.20M |
| December 31, 2020 | 1.070B |
| September 30, 2020 | -407.50M |
| June 30, 2020 | 813.50M |
| Date | Value |
|---|---|
| March 31, 2020 | 527.90M |
| December 31, 2019 | 648.40M |
| September 30, 2019 | 435.60M |
| June 30, 2019 | 93.70M |
| March 31, 2019 | 822.70M |
| December 31, 2018 | 643.37M |
| September 30, 2018 | 346.72M |
| June 30, 2018 | 282.55M |
| March 31, 2018 | 539.37M |
| December 31, 2017 | 459.29M |
| September 30, 2017 | 355.18M |
| June 30, 2017 | -85.42M |
| March 31, 2017 | 305.44M |
| December 31, 2016 | 227.42M |
| September 30, 2016 | 532.47M |
| June 30, 2016 | 260.66M |
| March 31, 2016 | -59.10M |
| December 31, 2015 | 104.04M |
| September 30, 2015 | 746.75M |
| June 30, 2015 | 3.713M |
| March 31, 2015 | -201.66M |
| December 31, 2014 | 80.74M |
| September 30, 2014 | 83.79M |
| June 30, 2014 | 256.92M |
| March 31, 2014 | -11.30M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Incyte Corp. | 495.25M |
| Amgen, Inc. | 3.489B |
| Vertex Pharmaceuticals, Inc. | 1.013B |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Gilead Sciences, Inc. | 3.433B |